{"id":"W2114612266","doi":"10.1200/jco.2006.07.6547","title":"Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Erlotinib; Internal medicine; Head and neck squamous-cell carcinoma; Phases of clinical research; Toxicity; Erlotinib Hydrochloride; Oncology; Cisplatin; Head and neck cancer; Gastroenterology; Progressive disease; Chemotherapy; Clinical endpoint; Cancer; Epidermal growth factor receptor; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002713038,0.001663804,0.002559314,0.0003588634,0.000429168,0.0008903671,0.001062585,0.001211073,0.002916452],"category_scores_gemma":[0.001109925,0.0006246995,0.001400195,0.0004479738,0.0008635079,0.0006420246,0.0003419088,0.002377063,0.0005990858],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00176113,"about_ca_system_score_gemma":0.003162942,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003532177,"about_ca_topic_score_gemma":0.01152391,"domain_scores_codex":[0.9992338,0.0004390755,0.00003886278,0.0001071447,0.00008504716,0.000096119],"domain_scores_gemma":[0.9991519,0.0001048003,0.0002135913,0.00006632391,0.00007597899,0.000387384],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8537259,0.04060375,0.009243582,0.00102538,0.00221865,0.0002356758,0.0002464964,0.002598304,0.02019591,0.0001858909,0.004931403,0.06478899],"study_design_scores_gemma":[0.8352929,0.1488485,0.01145362,0.00003044825,0.000472737,0.0001666427,0.00003058002,0.001011949,0.001159154,0.00006216628,0.001450087,0.00002118959],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890068,0.002472788,0.0004991989,0.0004888838,0.0001042406,0.004949716,0.0009756598,0.00005688396,0.001445846],"genre_scores_gemma":[0.9818867,0.002567592,0.00240059,0.001142429,0.0001799759,0.005571513,0.002989368,0.00002541966,0.003236285],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003532177,"threshold_uncertainty_score":0.01434809,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1661829989492623,"score_gpt":0.5044481561739024,"score_spread":0.3382651572246401,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}